Atara Biotherapeutics (ATRA) EPS (Basic) Growth (1y) (2014 - 2026)
Atara Biotherapeutics (ATRA) EPS (Basic) Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | -16.29% |
| 10 | Atara Biotherapeutics | 143.57 Mn | 127.01 Mn | 439,000.00 | -264.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -275.42% |
| Mar 31, 2026 | -108.34% |
| Dec 31, 2025 | 84.07% |
| Sep 30, 2025 | 89.19% |
| Jun 30, 2025 | 106.31% |
| Mar 31, 2025 | 162.54% |
| Dec 31, 2024 | 88.12% |
| Sep 30, 2024 | 82.11% |
| Jun 30, 2024 | 81.67% |
| Mar 31, 2024 | 68.60% |
| Dec 31, 2023 | 21.94% |
| Sep 30, 2023 | 20.10% |
| Jun 30, 2023 | -472.29% |
| Mar 31, 2023 | 17.78% |
| Dec 31, 2022 | 26.79% |
| Sep 30, 2022 | 9.23% |
| Jun 30, 2022 | 119.99% |
| Mar 31, 2022 | -2.12% |
| Dec 31, 2021 | 9.13% |
| Sep 30, 2021 | 1.24% |